Pretracheal Lymph Node CT Imaging Characteristics
On contrast-enhanced CT, pretracheal lymph nodes appear as soft tissue density structures located in the pretracheal retrocaval space at the level of the azygous arch, typically measuring 5.5 ± 2.8 mm in diameter, with normal nodes visible in approximately 88% of patients.
Normal Anatomic Location and Appearance
The pretracheal retrocaval (PTRC) space is precisely delineated by following the trachea anteriorly, azygous arch posteriorly, superior vena cava laterally, and aorta medially 1. This anatomic compartment is best visualized at the level where the azygous vein enters the posterior aspect of the superior vena cava.
Size Characteristics
- Normal pretracheal (azygous) lymph nodes: Mean diameter of 5.5 ± 2.8 mm 1
- Detection rate: Visible in 88.1% of normal subjects 1
- Multiple nodes: Present in 29.9% of subjects, with up to three nodes visible in some cases 1
- Upper limit of normal: Nodes up to 10 mm can be normal, though 11 nodes larger than 10 mm were identified in the normal population study 1
Density and Enhancement
The mean density of the PTRC space varies from -107 to +48 Hounsfield units (HU), with negative values predominating in most subjects due to mediastinal fat 1. The space increases significantly with mediastinal adiposity, age, and aortic unfolding.
Pathologic Features on Contrast-Enhanced CT
For detecting lymph node metastasis, a maximal axial diameter ≥5 mm on contrast-enhanced CT provides 70% sensitivity and 36% specificity 2. However, size alone is insufficient for accurate diagnosis.
Critical Pathologic Features
Poor-contrast areas (necrosis) within lymph nodes are highly specific for metastatic disease, with 95% specificity on contrast-enhanced CT 3. This finding is more reliable than size criteria alone.
Additional concerning features include:
- Heterogeneous enhancement pattern (independent predictor of malignancy) 4
- Necrotic centers with peripheral rim enhancement 5
- Extranodal extension 5
Technical Considerations for Optimal Imaging
Contrast Enhancement Protocol
Use 300 mg iodine/mL concentration at 0.5-1.0 mL/s flow rate to achieve optimal vascular enhancement (>60 HU) throughout the scan period 6. This ensures clear differentiation between vascular structures and lymph nodes.
Section Thickness
5 mm thick sections without contrast identify more mediastinal lymph nodes than 10 mm sections with contrast 7. However, for clinical staging purposes, contrast-enhanced CT remains essential for detecting necrosis and assessing vascular relationships 8.
Clinical Context and Pitfalls
Common Diagnostic Challenges
- Station 2R (right upper paratracheal): Shows greatest variability between observers and techniques, with contrast-enhanced CT revealing 54% more enlarged nodes than unenhanced studies 9
- False positives: Radiation injury can mimic malignancy with tumefactive appearance and marked enhancement 5
- Vascular mimics: Intravenous contrast is essential to distinguish lymph nodes from adjacent vascular structures, particularly when planning biopsies 10
When to Suspect Metastatic Disease
Consider malignancy when:
- Poor-contrast areas present (95% specificity) 3
- Heterogeneous enhancement pattern 4
- Associated with subglottic tumor extension or clinical positive neck status (combined sensitivity 90-100%) 2
- Focal intense FDG uptake on PET/CT, even if subcentimeter 5
Contrast-enhanced CT or MRI is strongly recommended for any neck mass at risk for malignancy per American Academy of Otolaryngology guidelines 8, as intravenous contrast is essential for detecting necrosis and guiding primary tumor search.